BioCentury
ARTICLE | Company News

Hisamitsu neurology, inflammation, endocrine/metabolic news

May 26, 2014 7:00 AM UTC

Hisamitsu announced a five-year plan to achieve annual sales of ¥190 billion ($1.9 billion) in its FY18 ending February 2019. The target would be a 26% increase over sales of ¥150.6 billion ($1.5 billion) for the FY13 ending February 2014. Hisamitsu plans to further expand the presence in Japan of its prescription and OTC businesses by modifying products to make them easier to use, maintaining sales of pain relieving anti-inflammatory patches, increasing sales of new products and expanding its lineup of items sold in orthopedic and pain areas.

Hisamitsu also will establish Hisamitsu Asia to oversee sales and production operations in Vietnam, Indonesia and Beijing, China, and expand the use of production facilities of its Noven Pharmaceuticals Inc. U.S. subsidiary. Additionally, the pharma said it will perform "exhaustive searches for new drug candidates and active alliances." ...